Octreotide Added to a Proton Pump Inhibitor Versus a Proton Pump Inhibitor Alone in Nonvariceal Upper-Gastrointestinal Bleeds.

Conclusion and Relevance: Our study observed no difference in clinical end points. This suggests that octreotide provides no additional major clinical benefit in NVUGIB, and PPI therapy alone may be sufficient.
PMID: 30803243 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - February 25, 2019 Category: Drugs & Pharmacology Authors: Riha HM, Wilkinson R, Twilla J, Harris LJ, Kimmons LA, Kocak M, Van Berkel MA Tags: Ann Pharmacother Source Type: research